Profile of non-compliance in lymphoblastic leukaemia.

Investigation of TEL/AML1 and BCR/ABL Fusion Genes in Patients Affected by Acute Lymphoblastic Leukaemia Using Interphase in situ Hybridization

Gene variants of CYP1A1 and CYP2D6 and the risk of childhood acute lymphoblastic leukaemia; outcome of a case control study from Kashmir, India

Studies on associations of various polymorphisms in xenobiotic metabolizing genes with different cancers including acute lymphoblastic leukaemia (ALL) are mixed and inconclusive. The current study analyzed the relationship between polymorphisms of phase I xenobiotic metabolizing enzymes, cytochromes P450 1A1 (CYP1A1) and CYP2D6 and childhood ALL in Kashmir, India. We recruited 200 confirmed ALL...

Immunophenotypic Subtyping of Leukemic Cells from Iranian Patients with Acute Lymphoblastic Leukaemia: Association to Disease Outcome

Background: Immunophenotypic characterization of the leukemic cells has been widely used as a tool for diagnosis, classification, stratification and prognosis of leukaemia. Objective: To investigate the immunophenotypic subtype profiles of Iranian patients with acute lymphoblastic leukemia (ALL) and its association to disease outcome. Methods: In this study, a total of 60 Iranian patients with ...

Cerebral Infarction in Childhood Acute Lymphoblastic Leukaemia Treated with Low Dose E. coli Asparaginase

Received September 16, 2005 Abstract The occurrence of thrombosis complicating L-asparaginase therapy in childhood acute lymphoblastic leukaemia has been supported by both laboratory and clinical evidences, but the exact pathogenic mechanism and predisposing factors remain elusive. Two children with acute lymphoblastic leukaemia (ALL) treated with chemotherapy developed cerebral infarction duri...

Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics

The impact of thiopurine methyltransferase (TPMT) genotype on thiopurine dose intensity, myelosuppression and treatment outcome was investigated in the United Kingdom childhood acute lymphoblastic leukaemia (ALL) trial ALL97. TPMT heterozygotes had significantly more frequent cytopenias and therefore required dose adjustments below target levels significantly more often than TPMT wild-type pati...